What is Myelofibrosis?

Myelofibrosis (MF) is a serious, rare bone marrow disorder that disrupts production of blood cells by extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and often an enlarged spleen. Current therapies offer symptom relief and minimal impact on underlying course of the disease.

The TRANSFORM-2 Study

The investigational medication, called navitoclax, is a drug that is being studied in people with myelofibrosis. Navitoclax works by targeting and killing cells causing bone marrow dysfunction in myelofibrosis.

In this study, the investigational medication (navitoclax) in combination with ruxolitinib will be compared to best available therapy to evaluate its effect on splenomegaly (enlarged spleen), bone marrow fibrosis, and anemia responses as well as quality of life.

You should ask your doctor if you have any questions about the investigational medication, including potential side effects, and standard treatments that are available for Myelofibrosis.

What should I do if I still have questions?

Don't be shy about asking questions of the study doctor or staff to understand whether participating is right for you. You may also find useful resources online.

Here are some examples that can help you:

- Learn more about what participating may mean for you by visiting AbbVie's online resource **ClinicalTrialsAndMe.com**
- Understand more about myelofibrosis **lls.org/myeloproliferative-neoplasms/myelofibrosis**

abbvie



TRANSFORM 2
M20-178

Research Study for Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

What is a clinical research study?

A clinical research study is medical research to learn more about investigational new drugs or unapproved new drugs. Clinical research studies help us understand safety and effectiveness of the investigational medication being researched.

Patients have different reasons for participating in clinical research, including:

- Contributing to the advancement of science
- Gaining access to investigational medications or study procedures

TRANSFORM-2 is a Phase 3 study using the investigational drug navitoclax in combination with ruxolitinib. Navitoclax has not been approved by regulatory agencies. Efficacy and safety have not been established. During this phase of a study, researchers need to confirm the effectiveness of the investigational medication and monitor its side effects in a large group of study participants.

Whatever your reasons, if you decide to participate, we will closely monitor your health and protect your privacy.

TRANSFORM 2
M20-178

Who can participate in this study?

TRANSFORM-2 is now enrolling patients for a clinical research study involving an investigational drug.

You may qualify to participate if you meet the following requirements:

- 18 years of age or older
- Diagnosed with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis
- Currently have Intermediate-2 or High-Risk myelofibrosis
- Have received prior treatment with a single JAK2 inhibitor therapy
- Have splenomegaly (enlarged spleen)

If you meet these criteria and are interested in more information, please contact your doctor to discuss the TRANSFORM-2 study and determine if you are eligible to participate.

Your participation in the study is voluntary – you can stop participating at any time for any reason.

Version 1 01July2020
INBC-AA-0008-RM, Version 1.0
Approved: 07/2020
Abbvie, Inc.